NCT00445965
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GD1/2
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain, Leptomeningeal disease
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT00445965